NCT00319852View on ClinicalTrials.gov

Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV

PHASE3CompletedINTERVENTIONAL
Enrollment

442

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

July 31, 2008

Conditions
PertussisDiphtheriaPoliomyelitisTetanus
Interventions
BIOLOGICAL

DTaP-IPV combined vaccine

0.5 mL, IM

BIOLOGICAL

DTaP vaccine

0.5 mL, IM

Trial Locations (1)

Unknown

Seoul

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY